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Background: Cigarette smoking is a leading cause of mortality and morbidity and is associated with cardiovascular
disease via contributory processes such as endothelial dysfunction, inflammation and thrombosis. Cigarette smoke
both contains and stimulates the production of cellular oxidants and it may also promote vascular inflammation.
Osteopontin is a non-collagenous matrix protein first identified in bone and there is increasing evidence for its role
in inflammation and cardiovascular disease via its action as a soluble cytokine.
Methods: In this study we have examined the mechanisms underlying the expression of osteopontin in human
vascular endothelial cells in vitro following exposure to cigarette smoke particulate matter (PM), using PCR,
electrochemiluminescence, immunostaining and Western blotting. We further determined if serum osteopontin
levels changed in humans who quit smoking.
Results: Non-cytotoxic concentrations of PM increased osteopontin levels in cultured human endothelial cells and
this effect was reduced in the presence of ascorbate, suggesting a role for oxidants in the response to PM.
However, oxidant production played no role in the PM-evoked induction MMP-3, an enzyme which cleaves
osteopontin. In smokers who quit smoking for 5 days, serum osteopontin levels were significantly lowered
compared to those measured prior to smoking cessation.
Conclusions: In vitro cigarette smoke extract exposure induced osteopontin expression in human endothelial cells
in an oxidative stress-dependent manner, which may involve MMP-3 cleavage. In humans, serum osteopontin was
decreased with short-term smoking cessation. Endothelial-derived osteopontin may contribute to inflammation in
smokers, and may also contribute to atherosclerosis and cardiovascular disease-related processes.
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Atherosclerotic cardiovascular disease is a leading cause
of mortality and morbidity worldwide [1-3]. Numerous
risk factors including genetic predisposition, diet, life-
style and smoking status affect the likelihood of an indi-
vidual developing cardiovascular disease, specifically
atherosclerosis. Cigarette smoking has a long-standing
association with cardiovascular disease and there is a
wealth of evidence concerning the effects of smoking on
key pathological processes such as vascular injury,* Correspondence: ian_fearon@bat.com
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reproduction in any medium, provided the orvascular dysfunction, inflammation and thrombosis [3].
Cigarette smoke is a complex and dynamic mixture of
more than 5,600 identified chemical constituents [4],
many of which may interfere with a number of cellular
processes and promote atherosclerosis [5]. Presently, a
full understanding of the mechanisms underlying the
susceptibility of smokers to cardiovascular disease is
lacking, as is our knowledge concerning which smoke
constituents, either individually or in combination with
others, contribute to its pathogenesis. Greater under-
standing of the mechanisms and chemical constituents
involved and biological changes that occur with smoking
cessation could aid in the treatment and prevention of
smoking-induced cardiovascular disease.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6] which was first identified as a component of bone
and is involved in bone formation and calcification [7].
Recent studies have shown an emerging and more wide-
spread role for osteopontin in inflammation, tissue re-
modelling and vascular disease via its action as an
inflammatory cytokine [8-10]. Soluble osteopontin inter-
acts with cell surface integrins to regulate cell adhesion,
migration and proliferation. Thrombin and matrix
metalloproteinases (MMPs) can differentially cleave
osteopontin at the amino acid sequence glycine-argin-
ine-glycine-aspartic acid-serine (termed the GRGDS)
motif which can disrupt integrin binding, ultimately
altering cellular responses [8]. MMP-regulated osteo-
pontin is also suggested to have a role in tissue injury
[11]. Clinical studies have strengthened the association
between osteopontin and cardiovascular disease and
osteopontin is now thought to represent a biomarker of
both the progression and severity of coronary artery dis-
ease [12], as well as a therapeutic target for cardiovascu-
lar disease interventions [13]. Osteopontin is expressed
by macrophages and acts as a potent macrophage-
chemotactic stimulus, regulating macrophage infiltration
and retention at sites of chronic inflammation [8].
Osteopontin expression has also been detected in angio-
genic endothelial cells, smooth muscle cells and macro-
phages from atherosclerotic plaques, suggestive of a role
in lesion remodelling [8].
Given the link between inflammation, atherosclerosis
and smoking, and also given the emerging evidence of a
role for osteopontin in cardiovascular disease, we have
examined the expression of osteopontin in endothelial
cells exposed to cigarette smoke in vitro and in smokers’
serum. Our findings advance our knowledge of the po-
tential role for this important inflammatory factor in
cigarette smoke-induced cardiovascular disease.
Methods
Cigarette smoke total particulate matter generation
Particulate matter from cigarette smoke was generated
using 3R4F reference cigarettes (University of Kentucky).
Cigarettes were conditioned for a minimum of 48 h at
22°C and 60% humidity (ISO 3402:1999) before smoking
on a RM20S smoking machine (Borgwaldt KC, Ham-
burg, Germany) under ISO standard conditions (35 ml
puff taken over 2 sec. every minute; ISO 3308:2000).
Smoke particulate matter (PM) was collected on a
Cambridge filter pad at a minimum of 250 mg tar per
pad. These are non-ISO standard conditions designed to
provide a higher yield of particulate matter than conven-
tionally achieved. PM was eluted with dimethylsulphox-
ide (DMSO) at 24 mg/ml and stored protected from
light in single use aliquots at -20°C for no longer than
1 month.Cell culture and treatment
Human umbilical vein endothelial cells (HUVECs;
Lifeline Cell Technology, California, U.S.A.) were main-
tained at 37°C in a 5% CO2 humidified atmosphere. Cells
were cultured in VascuLifeW VEGF media (Lifeline Cell
Technology) supplemented with VEGF (5 ng/ml), EGF
(5 ng/ml); basic FGF (5 ng/ml), IGF-1 (15 ng/ml), ascor-
bic acid (50 μg/ml), L-glutamine (10 mM), hydrocorti-
sone hemisuccinate (1.0 μg/ml), heparin sulphate (0.75
units/ml) and foetal bovine serum (2%). Cells were
seeded at 1×104 cells/ml for all assays with the exception
of PCR experiments where cells were seeded at 2x104
cells/ml. Cells were treated for 24 h either with PM or
with 1% DMSO as a diluent control. To examine the
contribution of oxidative stress in regulating osteopontin
levels, cells were incubated with the anti-oxidant ascor-
bate (200 μM) for 5 h prior to PM exposure.
Assessment of cell viability
Cell viability was measured by neutral red uptake assays.
In brief, HUVECs were incubated in 150 μl neutral red
solution diluted 1:65 in VascuLifeW VEGF media. Cells
were incubated for 3 h at 37°C to allow active uptake of
the dye into viable cells. Plates were washed twice in
PBS before the addition of 150 μl de-stain solution (50%
ethanol, 49% distilled water and 1% glacial acetic acid).
After 20 min. of agitation, the optical density was deter-
mined at 540 nm with a reference filter of 630 nm using
a microplate spectrophotometer (Thermo Labsystems,
Waltham, MA, U.S.A.). Background readings taken from
blank wells were subtracted from wells containing both
untreated and treated cells. Neutral red uptake was
expressed as a percentage of the level in untreated cells.
Quantification of osteopontin and MMP-3 gene
expression
Gene expression was assessed with the RT2 profiler™
PCR array system (SABiosciences) using an
atherosclerosis-specific panel. Cells were lysed using
TRIzolW reagent and centrifuged with chloroform. The
supernatant was added to an equal volume of isopropa-
nol and incubated at -20°C to precipitate RNA. Samples
were centrifuged to pellet mRNA followed by an ethanol
wash. Genomic DNA was eliminated using the supplied
First Strand Kit and mRNA was diluted to 1 μg total
mRNA. The components of the RT cocktail were com-
bined in a microfuge tube and added in equal volume to
RNA. The resultant mixture was incubated at 42°C for
15 min., after which the reaction was inactivated at 95°C
for 5 min. cDNA was diluted in dH20 and combined
with the PCR mastermix and 25 μl of solution was
added to each well of the array plate. The following ther-
mal cycler protocol was used: 10 min. at 95°C, 40 cycles
of 15 sec. at 95°C and 1 min. at 60°C.
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Osteopontin and MMP-3 levels were evaluated by electro-
chemiluminescence using the MSDW platform (Meso
Scale Discovery, MD, U.S.A.), in supernatants collected
from HUVEC cultures or sera from smokers and abstai-
ners. 25 μl of conditioned media or serum and calibrators
(0-100 ng/ml osteopontin, 0-2,500 pg/ml IL-6 and 0-
100 ng/ml MMP-3) were incubated with agitation on the
assay plate (osteopontin singleplex, ultrasensitive pro-
inflammatory-4 II (IL-6) MULTI-SPOTW and MMP-3-
plex MULTI-SPOTW 96-well small spot plates) for 1.5 h.
After this, SULFO-TAG anti-human osteopontin, anti-
human IL-6 or anti-human MMP-3 antibodies were added
to each well at 1 μg/ml. After a further 1.5-hour incuba-
tion period, plates were washed in 0.05% (v/v) PBS-
Tween-20 solution followed by the addition of 150 μl
Read Buffer. Plates were read using a MSDW SECTOR
2400 imager and protein concentration assessed against a
standard curve, using MSD WorkbenchW software.
Detection of osteopontin by immunocytochemistry
After PM treatment, HUVECs were washed in PBS and
fixed in ice-cold methanol for 15 min. Cells were then
blocked in PBS containing 2% BSA for 45 min at room
temperature. After two PBS washes, the cells were incu-
bated with 4 μg/ml rabbit anti-osteopontin polyclonal
antibody (Abcam, Cambridge, U.K.) for 1 h. The cells
were washed twice in PBS and incubated with 5 μg/ml
Alexa FluorW 568-labelled goat anti-rabbit antibody
(Invitrogen, Paisley, U.K.) for 1 h. Cells were further
washed with PBS and counterstained with DAPI (10 μg/
ml in PBS). Coverslips were mounted onto slides using
fluorescence mounting media (Dako, Denmark), viewed
with a TE2000 inverted fluorescence microscope (Nikon,
Surrey, U.K.) and images captured with an Orca 12-bit
camera (Hamamatsu, Japan). Images were taken of the
DAPI (blue) and osteopontin (red) channels using
IPLabTM software. Image data were quantified using
MetaMorphW software. Regions of interest were created
using a 70 × 70 pixel circle around the DAPI-stained nu-
cleus by examining only the blue channel. The red fluor-
escence of interest was then examined within this region
and the average pixel intensity of fluorescence in each
region of interest assessed. 10 nuclei per treatment were
evaluated.
Detection of osteopontin by western blotting
Whole-cell lysates were prepared by scraping cells off in
1 ml ice cold PBS and pelleting by centrifugation at
1500 g for 5 min. The resultant cell pellet was resus-
pended in 200 μl lysis buffer. Cell extracts were incu-
bated for 20 min at 65°C with reducing agent and
sample buffer. Equal amounts of proteins (25 μg perlane) were resolved on 12% SDS-polyacrylamide gels and
transferred to PVDF membranes. Membranes were
blocked using 5% non-fat dried milk solution in PBS
containing 0.1% (v/v) Tween-20 (PBST). Membranes
were probed for 1 h with either 1 μg/ml rabbit poly-
clonal osteopontin (Abcam, Cambridge, U.K.) or 0.5 μg/
ml mouse monoclonal β-actin (Sigma, Poole, U.K.) anti-
bodies. Membranes were washed in PBST and then incu-
bated with secondary 4 μg/ml goat anti-rabbit (Abcam,
Cambridge, U.K.) or 1:1000 goat anti-mouse (R&D sys-
tems, Minneapolis, U.S.A.) HRP-conjugated antibodies
with 1:3000 dilution Strep-TactinW HRP conjugate (Bio-
Rad, California, U.S.A) for a further hour with agitation.
Following two washes in 5% milk-PBST and one in
PBST, membranes were incubated in Immun-StarTM
WesternCTM chemiluminescence substrate (Bio-Rad) for
5 min before detection using an XRS Gel DocTM system
(Bio-Rad). Membrane images were evaluated using
Quantity OneW software. The molecular weights of
bands were calculated against the protein standard lanes
and quantified by average band density.
Obtaining sera from human smokers
A single-centre, randomized, controlled, open-label, par-
allel group clinical study (approved by an Institutional
Review Board) was conducted targeting enrolment of at
least 120 smokers smoking their usual brand of cigar-
ettes. U.S. adult smokers between 21 and 65 years old
were enrolled in the study. Subject inclusion/exclusion
criteria and baseline demographics can be found in Add-
itional file 1: Table S1. The study was conducted in com-
pliance with the principles of the Declaration of
Helsinki. The study protocol and informed consent
forms were reviewed and approved by the IntegReview
Ethical Review Board (Austin, Texas, USA; http://www.
integreview.com). Written, informed consent was
obtained from all study subjects before participating in
the study. This study was conducted according to the
applicable principles of the US Code of Federal Regula-
tions (CFR) governing the protection of human subjects
(21 CFR 50), financial disclosure by clinical investigators
(21 CFR 54), and IRBs (21 CFR 56).
Pre-study assessment (e.g. medical history, physical
exam, hematology, serology, virology, urinalysis) showed
that all subjects were generally healthy. Subjects were
confirmed to smoke between 19 and 25 cigarettes per
day and had been smoking for at least 3 years. Subjects
resided in the clinic for approximately 8 days. Smoking
status was verified during screening and daily in-clinic
by measuring exhaled carbon monoxide.
On Days −2 and −1 in clinic, all subjects acclimated to
smoking 20 cigarettes per day (20 CPD). The interven-
tion started on Day 1 and consisted of maintaining or
reducing to zero the number of CPD. On Day 1, subjects
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CPD, and 0 CPD). From Day 1 until the end of the study
on Day 5, subjects smoked up to the maximum allocated
number of CPD/group.
Blood was collected from subjects in the 20 CPD and
0 CPD groups on Day −1 and Day +5 and serum was
separated using BD diagnostics vacutainer serum separ-
ator tubes. After blood samples were drawn, tubes were
inverted 5–6 times and placed upright for ≤2 h. Tubes
were then centrifuged at 1300-2000 x g. Using dispos-
able pipettes, serum was transferred into 2 ml cryovials
and stored frozen at ≤ -80°C until analysis. Levels of
osteopontin in sera were determined using the MSDW
platform as described.
Data analysis and statistics
Data are expressed as means ± standard deviation (S.D.).
For both the in vitro studies and the osteopontin/IL-6
measurements in human sera, differences between treat-
ment means were examined using Student’s unpaired t-
tests. In the western blotting studies, data are expressed
as a ratio of osteopontin to β-actin band density. Data
were then normalised by dividing the band density of
the treatment group by that obtained in control
(DMSO-treated) cells.
Results
Concentration-dependent cytotoxicity of PM in
endothelial cells
To determine a non-cytotoxic range of cigarette smoke
PM concentrations, neutral red viability assays were
used to determine the cytotoxicity of PM exposure (0 to
200 μg/ml for 24 h) in human umbilical vein endothelial



















Figure 1 Cytotoxicity of cigarette smoke total particulate matter (PM
concentration of PM, cell viability was assessed using neutral red uptake as
donor, and data are representative of those obtained in 3 other donors. Da
the viability of cells not exposed to PM. *p < 0.05 compared to controls.that between 0 and 88 μg/ml there was a modest and in-
significant reduction in cell viability (p > 0.05 at each
concentration; Figure 1) which reached a value of
17.5 ± 16.3% (mean ± S.D., p = 0.1) at 88 μg/ml PM. At
higher concentrations, PM caused significant reductions
in cell viability. Thus, a 24-h exposure to PM at concen-
trations of 133 and 200 μg/ml elicited 43.32 ± 23.9%
(p = 0.04) and 92.7 ± 1.0% (p = 0.00001) reductions in via-
bility, respectively (Figure 2). Given these data, PM con-
centrations higher than 88 μg/ml were not used in
subsequent experiments.
PM exposure induced osteopontin gene expression
To assess the effects of PM on osteopontin expression
we exposed HUVECs from four different donors to
88 μg/ml PM for 24 h, after which gene expression was
examined using a multi-gene PCR array. PM exposure
caused osteopontin gene up-regulation of 2-fold or
greater when compared to dimethylsulphoxide (DMSO)
controls (Figure 2A) and this effect was consistently
observed in the four donors examined. The PM-induced
up-regulation was equal to or greater than the response
to the positive control agent tumour necrosis factor α
(10 ng/ml) in all donors tested (data not shown), indica-
tive of a strong PM response. All subsequent studies
were performed in a single donor (donor 4), chosen be-
cause other genes/proteins of interest were consistently
up-regulated in this donor and it was possible to obtain
more vials from this donor for additional investigations,
which assists in minimising inter-individual variability.
Effects of PM on osteopontin protein expression
To assess further the osteopontin response to PM
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Figure 2 Effects of PM treatment on osteopontin gene and protein expression. A, HUVECs from four different donors were exposed in
triplicate experiments to 88 μg/ml PM for 24 h. Gene expression was examined using a PCR array. Data are mean fold changes in gene expression
normalised to DMSO controls. B, 24-hour exposure to PM induced the secretion of osteopontin in a concentration dependent manner. Data are
mean± S.D. osteopontin concentrations (n = 6 in each case), as detected by electrochemiluminescence. *p < 0.05 compared to controls.
Bishop et al. BMC Cardiovascular Disorders 2012, 12:75 Page 5 of 10
http://www.biomedcentral.com/1471-2261/12/75supernatants of PM-treated HUVECs was measured by
electrochemiluminescence. As shown in Figure 2B, com-
pared to the DMSO control, PM treatment caused a
concentration-dependent increase in osteopontin secre-
tion. Thus, media osteopontin levels following a 24-hour
exposure to PM were 44.8± 38.3 ng/ml (p= 0.006),
64.8± 35.7 ng/ml (p= 0.00003), 79.7± 46.2 ng/ml
(p= 0.00004) and 118.3 ± 71.5 ng/ml (=0.00002) in cells
exposed to 6, 12, 24 and 48 μg/ml PM respectively (n= 6
at each concentration).
To further elucidate the effect of PM exposure on
osteopontin protein expression, experiments were con-
ducted using immunostaining and Western blotting. The
localisation and expression of cellular osteopontin
protein was visualised by immunocytochemistry, using
an antibody raised against amino acids 170-183
(CKSKKFRRPDIQPD) of the osteopontin peptide. When
compared to controls, PM treatment caused an increase
in osteopontin expression (Figure 3A). Quantification of
the immunostaining by pixel intensity analysis revealed
that PM at concentrations of 12, 24 and 48 μg/ml caused
increases in osteopontin expression from control levels
(109.7 ± 30.2 ng/ml) to 136.9 ± 25.5 ng/ml (24.7%,
p = 0.09), 149.5 ± 20.9 ng/ml (36.7%, p = 0.005) and
130.2 ± 18.0 ng/ml (19%, p = 0.03) respectively (n = 10 in
each case; Figure 3B). Western blotting studies further
revealed that PM exposure caused an increase in total
osteopontin protein compared to controls (Figure 3C).
Osteopontin was detected at ~66 kDa and quantification
of band densities showed that 48 μg/ml PM increased
the levels of osteopontin by approximately 25% com-
pared to the DMSO control (Figure 3D).A role for oxidative stress in the induction of osteopontin
production by PM
Since cigarette smoke is a rich source and also a
strong inducer of the cellular production of oxidants we
examined the effects of pre-treatment with the antioxi-
dant ascorbate (200 μM for 5 h) on the response to a
24-hour PM exposure. The supernatants of treated cul-
tures were collected and osteopontin levels assessed by
electrochemiluminescence. As shown in Figure 4A as-
corbate significantly reduced the degree of osteopontin
secretion in response to 24 and 48 μg/ml PM, causing
a 28% (51.7 ± 4.1 to 37.2 ± 4.3 ng/ml, p = 0.003) and
30% (80.3 ± 6.0 to 56.0 ± 5.2 ng/ml, p = 0.004) reduction
respectively (n = 6 at each concentration). Ascorbate
treatment alone had no significant effect of osteopontin se-
cretion compared to controls (n=6, p=0.27; Figure 4A).
This effect was also observed in immunocytochemistry
studies (Figure 4B) where pre-treatment of cells with as-
corbate reduced the PM-induced increase in immuno-
fluorescence, which was statistically significant at 24 and
48 μg/ml PM. Ascorbate alone had no significant effect
on osteopontin expression. Western blotting studies
(Figure 4C) further demonstrated that ascorbate pre-
treatment reduced PM-induced osteopontin expression.
Are MMPs involved in the PM-induced production of
osteopontin?
Full-length osteopontin can be cleaved by MMP-3 to
alter integrin binding and therefore cellular responses
[11]. To ascertain whether this affects PM-induced
osteopontin expression, Western blotting studies were
performed using an antibody that detects both the full-
PM DMSO A C 
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Figure 3 Localisation and expression of osteopontin following PM exposure. A, exemplar images from immunostaining studies showing
the induction of osteopontin expression upon PM treatment. B, results of pixel intensity analysis of images such as those shown in A. Data are
mean± S.D. pixel intensities from 10 cells at each concentration. *p < 0.05 compared to controls. C, Western blot analysis showed the presence of
osteopontin at 66 kDa, which was greater in cells treated with 48 μg/ml PM for 24 h. D, quantification of band densities showed a 25% increase
in osteopontin levels following PM exposure.
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osteopontin fragment. Bands at ~66 kDa (full-length
osteopontin) and ~33 kDa (MMP-3 cleaved) were identi-
fied following PM exposure (Figure 4C). Quantification
of band densities showed that 48 μg/ml PM increased
the levels of both the full-length and the MMP-
3-cleaved osteopontin when compared to the DMSO
controls. Pre-treatment of cells for 5 h with 200 μM as-
corbate reduced the levels of both the full-length and
the MMP-3-cleaved osteopontin proteins. Thus, MMP-3
cleavage may be involved in PM-induced osteopontin
production.
PM-induced expression of MMP-3 is independent of
oxidative stress
Since PM caused an increase in osteopontin expres-
sion via an oxidative stress-sensitive mechanism which
may involve MMP-3 cleavage of osteopontin, we
examined MMP-3 expression in HUVECs exposed to
PM. Using electrochemiluminescence we constructed
a concentration-response curve for the effects of PM
on MMP-3 protein levels (Figure 5A). PM concentra-
tions between 6 and 48 μg/ml PM caused significant
and concentration-dependent increases in MMP-3
levels. For example, at a PM concentration of 48 μg/ml PM secreted MMP-3 levels were 307.7 ± 33.7 pg/
ml, compared to 38.6 ± 33.4 pg/ml in DMSO-treated
controls (p = 0.00002, n = 6). In contrast to the effects
of PM on osteopontin expression, pre-incubation with
ascorbate had no effect on the MMP-3 response
(Figure 5B). Thus, at each concentration of PM (12,
24 and 48 μg/ml) MMP-3 protein levels in media
from cells pre-treated for 5 h with 200 μM ascorbate
prior to PM exposure were not significantly different
from those in cells exposed to PM alone (p = 0.4, 0.7
and 0.3 respectively, in each case, n = 6).
Osteopontin levels in sera from smokers and abstainers
Previous studies have shown that cigarette smoke pro-
motes oxidative stress by delivering free radicals and by
promoting the endogenous generation of free radicals
by activated vascular cells. The oxidative stress induced
by smoking is rapidly reversed on cessation [14-16]. To
assess the link between smoking, oxidative stress, in-
flammation and osteopontin expression, we measured
the levels of osteopontin protein in sera obtained from
healthy smokers who were initially smoking up to 20
cigarettes per day (20 CPD) and either continued to
smoke up to 20 CPD or refrained from smoking com-
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Figure 4 Induction of osteopontin expression by PM is oxidative stress-dependent. A, ascorbate pre-treatment (200 μM for 5 h) prior to a
24-hour exposure to 12, 24, or 48 μg/ml PM reduced osteopontin secretion compared to cells exposed to PM alone. Data are presented as
mean± S.D. osteopontin concentrations, as detected by electrochemiluminescence. N = 6 in each case. B, similar to the secretion studies,
immunocytochemistry showed that ascorbate pre-treatment blunted the increase in osteopontin immunostaining caused by PM exposure.
Graphical data are mean pixel intensities from 10 cells at each concentration. In A and B, *p < 0.05 compared to controls and #p< 0.05 compared
to PM alone. C, Western blotting studies detected the presence of bands at 66 kDa and 33 kDa representing full-length and MMP-3 cleaved
osteopontin, respectively. Ascorbate pre-treatment caused a reduction in the PM-induced elevation of osteopontin protein levels, which was
most prominent in the MMP-3 cleaved form. Lane one, DMSO; lane two, ascorbate alone; lane three, PM; and lane four, PM with ascorbate
pre-treatment. Graphical data are band densities obtained by densitometric analysis of Western blots.
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Day -1 and 10448.8 ± 1889.1 pg/ml on Day +5 (n= 20;
P = 0.68). In contrast, in those subjects in the 0 CPD group
who refrained from smoking for 5 days, osteopontin levels
were significantly decreased, from 10534.7 ± 2650.5 pg/mlon Day -1 to 9429.2± 2778.3 pg/ml on Day +5 (n= 20;
p =0.03). There was also no difference between groups at
Day -1 (p= 0.85). A change in the inflammation status of
individuals who quit smoking was evident in the 0 CPD

























































Figure 5 PM-induced MMP-3 elevation occurs independently of oxidative stress. A, PM induced a concentration-dependent increase in
MMP-3 levels. Data are mean ± S.D. MMP-3 levels were assessed by electrochemiluminescence in supernatants taken from treated cells. n = 6 in
each case. *p < 0.05 compared to controls. B, PM-induced MMP-3 expression was not affected by ascorbate pre-treatment. n = 6 in each case.
*p < 0.05 compared to controls. #, p > 0.05 compared to TPM alone.
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reduced from 2.25± 1.69 pg/ml on Day -1 to
1.89± 1.29 pg/ml on Day +5 (n= 20; p = 0.005).
Discussion
The interaction between cigarette smoke, oxidative
stress, inflammation and cardiovascular disease has been
widely reported [14] and there is increasing evidence of
a role for osteopontin as an inflammatory mediator in
atherosclerosis [6,8-12]. Here, we report that exposure
of endothelial cells to cigarette smoke PM in vitro
induced the expression of osteopontin, a previously
undescribed effect which may have important implica-
tions for our understanding of the association of smok-
ing with cardiovascular disease. While a similar effect
has previously been reported in human bronchial epithe-
lial cells [17], this is the first instance where osteopontin
production has been reported in response to cigarette
smoke exposure in endothelial cells. Thus, the endothe-
lium is a potential source of smoke-induced inflamma-
tory osteopontin protein and this may play a role in
cardiovascular disease. The mechanism of this endothe-
lial response likely involves oxidative stress since osteo-
pontin induction was diminished by treating cells with
the antioxidant, ascorbate. Furthermore, our studies
highlight a potential role for MMP cleavage in regulating
the levels of cleaved forms of osteopontin, which have
different functional attributes [11].
The analysis of gene expression was important to ver-
ify that cigarette smoke-induced changes in protein ex-
pression were due to transcriptional regulation and not
transient changes in local protein concentration. This
finding of altered osteopontin gene expression is inaccordance with the increased osteopontin mRNA ex-
pression seen in atherosclerotic plaques in vivo, a meas-
urement which closely associates with the severity of
atherosclerosis and plaque calcification [13]. This sug-
gests that the in vitro model used in this study to exam-
ine smoke-induced alteration of gene expression may be
an appropriate one in which to further examine the in-
flammatory and atherogenic effects of cigarette smoke
extracts.
Subsequent to the gene expression analysis we demon-
strated that osteopontin protein levels were elevated fol-
lowing cigarette smoke extract exposure and that this
effect was reduced by antioxidant pre-treatment.
Cigarette smoke is both a source and a cause of the pro-
duction of cellular reactive oxygen species. The pro-
inflammatory effects of cigarette smoke have been well
described [17-21] and these may occur through activa-
tion of oxidative stress-regulated transcription factors
such as NFκB or AP-1, which regulate the expression
levels of inflammatory mediators. Given our current
data, we propose that endothelial-derived osteopontin
may be a mediator of smoke- and oxidative stress-
induced inflammation with a role in the development
and/or progression of cardiovascular disease.
The functional effects of osteopontin are determined
not only by its expression levels but also by its cleavage
by various enzymes into functionally diverse fragments
[12]. The matrix metalloproteinase family of enzymes
regulate the accumulation of extracellular matrix and
contribute to the growth of the atherosclerotic plaque
and therefore its stability through excessive degradation
of plaque cellular matrix. In particular, MMP-3 has been
implicated as a strong regulator of vascular re-modelling
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increased risk of cardiac events [22]. As well as being
co-localised at sites of tissue injury [12], osteopontin has
been described as a substrate for MMP-3 and this may
modify its integrin binding properties as well as its abil-
ity to initiate downstream signalling events [11]. In this
study, we demonstrated that PM enhanced the expres-
sion of both the full-length and the MMP-3-cleaved
osteopontin fragments. Interestingly, PM-induced eleva-
tion of MMP-3 itself was ascorbate-insensitive. Oxida-
tive stress therefore may be differentially involved in the
production of functionally-dissimilar osteopontin frag-
ments and functional changes in osteopontin effects can
be mediated by cigarette smoke acting on distinct and
non-oxidative stress-dependent parts of the pathway.
Oxidative stress has been proposed to play a promin-
ent role in numerous smoking-related diseases including
atherosclerotic cardiovascular disease [14] and it has also
been shown that the oxidative stress induced by smoking
is rapidly reversible on cessation [15,16]. Given our data
obtained using an in vitro cardiovascular disease model
we hypothesised that, in a short-term study in subjects
who refrained from smoking, osteopontin levels would
be reduced. Our data presented here support this hy-
pothesis by demonstrating a decrease in serum osteo-
pontin levels in healthy subjects who quit smoking for
5 days, compared to a control group who continued to
smoke 20 cigarettes per day. While further studies are
needed to examine the longer-term effects of smoking
cessation on both biomarkers of oxidative stress/inflam-
mation and on the levels of osteopontin in serum, this
study indicates that osteopontin can be a potential
short-term biomarker of inflammation/oxidative stress.
Limitations
In the in vitro work performed in this study, we exam-
ined the expression of MMP-3 protein in HUVECs.
However, the expression level of MMP-3 is not the only
determinant of its activity. The functional activity of the
MMPs is also regulated by the tissue inhibitors of metal-
loproteinases (TIMPs) and the expression of TIMPs has
been shown to be affected by cigarette smoke exposure
[23,24]. Further studies are required to fully elucidate
the role of oxidative stress on the functional activity of
MMPs and its modulators, as well as on the impact of
this on osteopontin expression and function, in response
to cigarette smoke exposure.
In this study, we examined the levels of osteopontin
protein in human sera obtained from smokers who
abstained from smoking for 5 days. In this period, the
levels of osteopontin in these sera were reduced com-
pared to their levels prior to smoking abstinence. How-
ever, further studies would be required in order to
understand the long-term effects of smoking cessationon osteopontin levels in serum and to assess its involve-
ment in inflammation and its association with smoking-
related cardiovascular disease.
Conclusions
Cigarette smoke extracts induced osteopontin expression
in cultured vascular endothelial cells and we propose
that this may play a role in the pro-inflammatory effects
of cigarette smoke. In vitro the induction of the osteo-
pontin protein was oxidative stress-dependent, and
serum osteopontin levels were lowered in human sub-
jects whose oxidative stress/inflammatory burden had
likely been lowered by smoking cessation. Understanding
the role of the pro-inflammatory osteopontin protein in
cigarette smoke-induced pathogenesis and understand-
ing any reversible effects with smoking cessation will ad-
vance our overall understanding of cardiovascular
disease development and progression.
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